Article Sidebar
Views pdf: 21
ROLE OF PET/CT IN BREAST CANCER
Main Article Content
Abstract
Introduction: Breast cancer is one of the most common cancer in women. Accuracy stage diagnosis helps to treat the patient effectively and can prolong the patient's survival time. PET/CT is an effective modality of breast cancer diagnosis and staging.
Objective: This study evaluates the stage change of breast cancer after PET/CT scan, and also evaluates the level of FDG absorption according to the SULmax.
Subjects and methods: The study enrolled breast cancer patients undergoing PET/CT scan in 2020. The patients excluded patients who fell into the following situations: bilateral breast cancer, have other cancers, lack of information on disease stage, blood sugar when radioactive injection is greater than 200 mg/dL. The dose of FDG for patients is 0.1mCi/kg body weight. PET/CT scan from the skull to the upper thigh. Data is recorded before and after the capture. Data processing with MS Excel and SPSS 25.0. Methods: retrospective, descriptive case series
Results: After screening, 80 patients were included in the study. Of which, 47.5% are left breast cancers and 52.5% are right breast cancers. Purpose of PET/CT scan, 33.8% are taken to diagnose the stage and most of the rest are to evaluate recurrence and metastasis. Stage change after PET/CT was recorded as 47.5% with 45% stage increase and 2.5% stage reduction. When evaluating FDG absorption according to SULmax, primary tumors showed the highest absorption. Of the biological subgroups, the tripple negative subgroup had the highest mean absorption. Regarding detected metastatic lesions, lung-pleural metastases accounted for the highest rate with 38.25%. In addition, 26.27 % cases of metastasis from two organs were detected.
Conclusion: PET/CT enabled nearly half of the patients to be staged correctly and received adequate treatment. At the same time, the remaining patients are also treated with peace of mind according to the current strategy. PET/CT also helps to evaluate the glucose metabolism of malignant lesions or detect early recurrence and metastases without any morphological changes.
Article Details
Keywords
PET/CT, breast cancer, metastatic recurrence assessment, Oncology Hospital
References
2. M. S. M. J. A. William J. Gradishar, "NCCN Guidelines Version 5.2023," National Comprehensive Cancer Network, 2023.
3. E. L. Rosen, "FDG PET, PET/CT, and Breast Cancer Imaging," RG f Volume 27 Special Issue.
4. G. Ulaner, "PET/CT for patient with breast cancer: where is the clinical impact ?," American Journal of Roentgenology, , Vols. August 2019, V 213, Number 2, 2019.
5. M. Shawky, "Role of positron-emission tomography/ computed tomography (PET/CT) in breast cancer," Egyptian Journal of Radiology and Nuclear Medicine (2020) 51:125, 2020.
6. A. K. B. V. T. W. N. K. D. T. T. B. M. Bernsdorf1, "Preoperative PET/CT in early-stage breast cancer," in Published by Oxford University Press on behalf of the European Society for Medical Oncology, Copenhagen, 21 July 2011.
7. K. Paydary, "The Evolving Role of FDG-PET/CT in the Diagnosis, Staging, and Treatment of Breast Cancer," Molecular Imaging and Biology volume 21, pages1–10(2019), 2019.
8. J. H. O. a. R. Wahl, "Practical PERCIST 1.0," Society of Nuclear Medicine, vol. Vol. 54, no. Issue supplement 2, 2013.
9. D. Groheux, "18F-FDG PET/CT for Staging and Restaging of Breast Cancer," J Nucl Med , vol. 2016; 57:17S–26S, 2016.
10. C. D. c. Edouard Depardon, "FDG PET/CT for prognostic stratification of patients with metastatic breast cancer treated with first line systemic therapy: Comparison of EORTC criteria and PERCIST," PLOS ONE, July 16, 2018.